Linear mucosal defect may be characteristic of lansoprazole-associated collagenous colitis

Gastrointest Endosc. 2008 Jun;67(7):1185-91. doi: 10.1016/j.gie.2008.02.013.

Abstract

Background: Although some cases of collagenous colitis have been induced by lansoprazole (LPZ), the clinicopathologic features of LPZ-associated collagenous colitis have not been elucidated.

Objective: To elucidate the clinical, endoscopic, and histopathologic features of LPZ-associated collagenous colitis.

Design: Retrospective case study.

Patients: The subjects were 13 patients with collagenous colitis diagnosed during a period from 2002 to 2007.

Main outcome measurements: The colonoscopic and histopathologic findings were compared retrospectively between 9 cases of LPZ use (LPZ group) and 4 cases without the use of LPZ (non-LPZ group).

Results: A colonoscopy revealed a linear mucosal defect more frequently in the LPZ group (7 of 9 cases [78%]) than in the non-LPZ group (0 of 4 cases [0%], P = .02). Friable mucosa was also noted in 4 patients (44%) in the LPZ group but none in the non-LPZ group. The colonoscopic finding in the non-LPZ group was either normal mucosa or nonspecific minimal abnormalities, whereas patients in the LPZ group had either a linear mucosal defect, mucosal bleeding, or both (P = .001). On histologic examination, the subepithelial collagen band was thicker in patients in the LPZ group than in those in the non-LPZ group (median 45 vs 26.3 mum). All patients in the LPZ group recovered from diarrhea after discontinuance of LPZ.

Limitation: A small number of patients.

Conclusions: Linear mucosal defects and friable mucosa may be characteristic colonoscopic findings in cases of LPZ-associated collagenous colitis.

MeSH terms

  • 2-Pyridinylmethylsulfinylbenzimidazoles / adverse effects*
  • 2-Pyridinylmethylsulfinylbenzimidazoles / therapeutic use
  • Adult
  • Aged
  • Aged, 80 and over
  • Case-Control Studies
  • Colitis, Collagenous / chemically induced*
  • Colitis, Collagenous / diagnosis
  • Colitis, Collagenous / pathology*
  • Colonoscopy / methods
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Gastroesophageal Reflux / diagnosis
  • Gastroesophageal Reflux / drug therapy
  • Humans
  • Intestinal Mucosa / pathology*
  • Lansoprazole
  • Male
  • Middle Aged
  • Proton Pump Inhibitors*
  • Proton Pumps / adverse effects
  • Reference Values
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index

Substances

  • 2-Pyridinylmethylsulfinylbenzimidazoles
  • Proton Pump Inhibitors
  • Proton Pumps
  • Lansoprazole